Cytos Biotechnology Presents Results for Melanoma Vaccine

Swiss drugmaker Cytos Biotechnology reported results from three Phase IIa clinical trials with CYT004-MelQbG10, a therapeutic vaccine to treat malignant melanoma.

The parallel, open-label studies included 22 patients with Stages II–IV malignant melanoma. The studies assessed safety, tolerability and T cell immunogenicity of three different dose regimens of CYT004-MelQbG10 and also compared two different routes of administration.

All dose regimes were safe and well tolerated, and reported adverse events included mostly mild to moderate injection site reactions.

Seven of 22 patients entered the study without detectable tumor after surgical intervention. Six of these patients remained tumor-free throughout the study period and one developed new metastases.

The remaining 15 participants entered the study with detectable metastases. Two of the 11 patients with progressive disease died; one had stable disease; one showed a partial response; one was not assessable since the tumor lesion was removed during the trial; and one died before the final assessment, Cytos said.